Core Viewpoint - KDventures AB announces the discontinuation of the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) by Organon, leading to a complete write-off of the remaining book value of the agreement related to the acquisition of Forendo [1][2][3]. Group 1: Company Developments - Organon has halted the development of both drug candidates acquired from KDventures' portfolio company Forendo, including the advanced drug candidate OG-6219 for endometriosis [2]. - The decision to discontinue the PCOS drug candidate means that KDventures will write off the entire value of the agreement concerning potential additional purchase considerations [1][3]. Group 2: Financial Implications - The write-off will be reflected in KDventures' interim report for the first quarter of 2026, indicating a significant impact on the company's financial statements [3]. Group 3: Company Background - KDventures AB is a Nordic investment company focused on life sciences, investing in innovative pharmaceutical projects and medical technology products from leading research institutions in the Nordic region [4]. - The company aims to create value through a diversified portfolio and professional due diligence, offering investors exposure to both listed and private life science projects with high growth potential [4].

As filed with the Securities and Exchange Commission on September 26, 2023 Registration No. 333-274511 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT No. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SWK HOLDINGS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 6159 77-0435679 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificat ...